MyMD’s lead drug candidate, MYMD-1, is in development to target aging and related diseases as well as autoimmune diseases including rheumatoid arthritis
BALTIMORE, October 26, 2021– (COMMERCIAL THREAD) –MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (âMyMDâ or âthe Companyâ), a clinical-stage pharmaceutical company committed to extending healthy lifespan, today announced that Chris Chapman, MD, president, chief executive officer and medical director of MyMD, will be honored by the Arthritis Foundation as Honored Doctor of 2021, which will be presented at the annual meeting Commitment to a Healing Gala to be held on October 28, 2021 in Washington, DC
This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/20211026005789/en/
Chris Chapman, MD, President, CEO and Medical Director of MyMD Pharmaceuticals, Inc. (Photo: Business Wire)
âI am deeply honored by this recognition from The Arthritis Foundation and proud to be associated with this much-loved organization, consistently ranked among the top charities in the United States,â said Dr. Chapman. âArthritis is the leading cause of disability in the United States, and the Foundation’s dedication to preventing, controlling and curing this disease has a huge impact on millions of Americans every year. MyMD joins the Arthritis Foundation in its mission to beat arthritis with life-changing science. , notably thanks to our clinical stage immunometabolic regulator MYMD-1 which targets the root causes of inflammation and has been shown to be effective in the treatment of autoimmune diseases in animal models. “
Greta Barnes, Executive Director of Metro DC Market for the Arthritis Foundation, said: âThis honor is most fitting for Dr. Chapman, a highly accomplished medical leader at the forefront of drug discovery for autoimmune diseases, including arthritis. MyMD’s drug candidate, MYMD-1, could represent a transformational therapeutic solution for people suffering from the pain, inflammation and joint destruction of this devastating disease. The Arthritis Foundation gratefully acknowledges Dr. Chapman and MyMD Pharmaceuticals for their commitment to our common cause.
All proceeds from the Arthritis Foundation’s Commitment to a Cure Gala support the Arthritis Foundation’s efforts to fight disease and help more than 54 million Americans.
MyMD’s lead drug candidate, MYMD-1, is under development to target aging, age-related diseases, and autoimmune diseases, including rheumatoid arthritis. MYMD-1 addresses the root causes of autoimmune diseases by targeting pro-inflammatory cytokines, primarily tumor necrosis factor alpha (TNF-Î±), which are active in autoimmune diseases, aging and certain types of depression. The increasing prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease is driving demand for TNF inhibitors like MYMD-1. Studies estimate that the number of people with rheumatoid arthritis could reach more than 78 million by 2040.1
MyMD plans to advance MYMD-1 in the clinic with two concurrent Phase 2 trials starting this quarter, one for delaying aging and prolonging healthy lifespan, and the second for depression associated with COVID-19 and the elevation of cytokines.
Dr Chapman Bio
Dr. Chapman is a seasoned executive and global medical expert with extensive experience in clinical trial design and protocols and in the conduct of clinical trials. Prior to joining MyMD and since 1999, Dr Chapman headed Chapman Pharmaceutical Consulting, Inc., an organization that provides support to pharmaceutical and biotechnology companies in North America, Europe, Japan, India and Africa on issues such as as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. He is also the founder of Chapman Pharmaceutical Health Foundation, a non-profit organization established to raise public funds and address health care needs such as AIDS, diabetes, hypertension, lupus, sickle cell disease, malaria and tuberculosis. Dr. Chapman’s career includes leadership roles with Organon Pharmaceuticals and Quintiles (now known as IQVIA), a member of the board of directors of Rock Creek Pharmaceuticals, Inc. He also spent two years as a physician in intensive care among staff at Doctor’s Community Hospital in Lanham, Maryland.
Dr. Chapman graduated from Georgetown University in Washington, DC in 1987. He completed his internship in internal medicine, residency in anesthesiology, and fellowship in cardiovascular and obstetric anesthesiology at Georgetown. Prior to his time in Georgetown, Dr. Chapman served in the United States Air Force as a crew chief on a B-52 during the Vietnam era. Dr. Chapman served at Ellsworth Air Force Base in South Dakota, Andersen Air Force Base in Guam; Royal Thai Navy base U-Tapao in Thailand; and Kadena Air Base in Japan.
Dr Chapman graduated from Harvard Kennedy School, Cambridge, Massachusetts, in Financial Management (2020).
About the Arthritis Foundation
The Arthritis Foundation fights for all people who live with arthritis. As a champion of Yes, the mission of the Arthritis Foundation is to turn the barriers caused by arthritis into opportunities. The Arthritis Foundation champions life-changing solutions and medical advancements, and it also empowers people to connect, break down barriers in healthcare and join the fight. for a cure – uniting hearts, minds and resources to change the future of arthritis. To join the fight against arthritis, visit arthritis.org.
The primary goal of MYMD-1 is to slow down the aging process and extend healthy lifespan, and it also shows promise as a potential treatment for post-COVID-19 complications and as an anti- fibrosing and anti-prolific. MYMD-1 has been shown to be effective in regulating the immune system by acting as a selective inhibitor of tumor necrosis factor alpha (TNF-Î±), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-Î± when it becomes overactivated in autoimmune diseases and cytokine storms, but does not prevent it from doing its normal job of first responder to any type of routine moderate infection. The ease of oral administration of MYMD-1 is another difference from currently available TNF-Î± blockers, all of which require administration by injection or infusion. No approved TNF inhibitor has ever been administered orally. Additionally, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. MyMD plans to launch two Phase 2 trials during the current quarter for MYMD-1 – one for delaying aging and extending healthy lifespan, and the other for post-COVID-19 depression and elevation of cytokines.
About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical-stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two new therapeutic platforms that address the causes of disease rather than just treating symptoms. MYMD-1 is a clinical-stage small molecule drug platform that regulates the immune system to control TNF-Î±, which causes chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and depression associated with COVID-19. The Company’s second drug platform, Supera-CBD, is in development to treat chronic pain, drug addiction and epilepsy. Supera-CBD is a new synthetic derivative of cannabidiol (CBD) and is being developed to respond to and improve the rapidly growing CBD market, which includes both FDA-approved drugs and non-CBD products. currently regulated as drugs. For more information visit www.mymd.com.
Caution regarding forward-looking statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from expected future results, performance or achievements. Forward-looking statements speak only as of the date on which they are made, and neither MyMD nor its affiliates assumes any duty to update any forward-looking statements. Words such as âanticipateâ, âbelieveâ, âcouldâ, âestimateâ, âexpectâ, âcanâ, â/? Important factors that could cause actual results to differ materially from those indicated by these forward-looking statements include, but are not limited to: the timing and ability of MyMD to obtain and maintain regulatory approvals for candidate clinical trials Pharmaceuticals from MyMD; the schedule and results of clinical trials planned by MyMD for its pharmaceutical candidates; the amount of funds required by MyMD for its pharmaceutical candidates; increased levels of competition; changes in general political, economic or regulatory conditions and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; the ability of MyMD to respond quickly and effectively to new technological developments; MyMD’s ability to protect its trade and other secrets of proprietary rights, operate without infringing the proprietary rights of others, and prevent others from infringing upon the proprietary rights of MyMD; and the impact of the ongoing COVID-19 pandemic on MyMD’s operating results, business plan and global economy. A discussion of these and other factors relating to MyMD is set out in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed by MyMD on August 16, 2021. Forward-looking statements speak only as of from the date on which they are made and MyMD disclaims any intention or obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise.
1 Data published by Research and Markets, March 2018.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211026005789/en/